Evidence map›Paper›PMID 42682043›Full record

ReviewThe Canadian journal of urology2026

Ketamine uropathy: an update on pathophysiology, complications, and treatment options.

Derrick Tsang, Ioannis Loufopoulos, Konstantinos Kapriniotis, Hannah Danbury, Ioannis Manolitsis, Stamatios Katsimperis, Senol Tonyali, Patrick Juliebø-Jones, Lazaros Tzelves, Neha Sihra and 1 more

Abstract readReview
PubMed Publisher
In one paragraph

Review in The Canadian journal of urology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Derrick TsangDepartment of Urology, Whipps Cross University Hospital, London, UK.
Ioannis LoufopoulosDepartment of Urology, Royal Free Hospital, London, UK.
Konstantinos KapriniotisDepartment of Urology, Whipps Cross University Hospital, London, UK.
Hannah DanburyDepartment of Urology, Royal Free Hospital, London, UK.
Ioannis ManolitsisSecond Department of Urology, National and Kapodistrian University of Athens, Athens, Greece.
Stamatios KatsimperisSecond Department of Urology, National and Kapodistrian University of Athens, Athens, Greece.
Senol TonyaliDepartment of Urology, Istanbul Faculty of Medicine, Istanbul, Türkiye.
Patrick Juliebø-JonesDepartment of Clinical Medicine, University of Bergen, Bergen, Norway.
Lazaros TzelvesDepartment of Urology, Royal Free Hospital, London, UK.
Neha SihraDepartment of Urology, The Royal London Hospital, London, UK.
James GreenDepartment of Urology, Whipps Cross University Hospital, London, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ketamine is a potent anaesthetic drug that has been used for decades. Ketamine abuse is an increasingly common problem, particularly among young people. Over one quarter of ketamine users will have at least one bothersome urological symptom, with heavier and longer use leading to potentially irreversible damage to the lower and upper urinary tract. Hence, this study carried out a narrative review focusing on ketamine-induced uropathy pathophysiology, clinical presentation, and treatment options. It was found that ketamine uropathy is an inflammatory condition affecting predominantly the bladder but also the upper urinary tracts. A hypersensitivity reaction to the drug has been proposed as the potential pathophysiological mechanism that causes inflammatory reaction, muscle hypertrophy, and non-reversible fibrosis in the advanced stages of the disease. Abstinence from ketamine use is the cornerstone of treatment at any stage of the disease, with effective pain management and psychological support being critical to reduce ketamine seeking behaviours. For mildly symptomatic patients, minimally invasive options such as bladder instillations and intravesical Botox injections can provide symptomatic relief. For more severe cases with refractory symptoms and upper urinary tract involvement, reconstructive urological operations might be necessary, including augmentation cystoplasty, cystectomy, or ureteric reconstruction. Ongoing surveillance of the upper tracts is recommended for both groups of patients. Ketamine induced uropathy is an increasingly prevalent condition, and ketamine abuse should always be inquired about in people with unexplained lower urinary tract symptoms. Adequate information of the public regarding ketamine abuse and early consultation with a urologist might prevent irreversible damage.

Indexed as

Anesthetics, DissociativeKetamineSubstance-Related DisordersUrologic DiseasesHumansAnesthetics, DissociativeKetaminebladder painharm reductionketamine uropathylower urinary tract symptoms (LUTS)reconstruction

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.